In the first newsletter, SNP-its highlights articles about
- CYP2C19 poor metabolizers may need a four-fold dose increase for clopidogrel
- CYP2D6 drug interactions may decrease response to hydrocodone and increase response to ondansetron
- personalized medicine in cardiology and oncology in Europe.
PharmGKB is pleased to work with the SNP-its initiative to highlight articles with these summaries on our website in the coming weeks. Look for the SNP-its icon on PharmGKB!